Management of haemorrhagic type moyamoya disease with intraventricular haemorrhage during pregnancy

Acta Neurochir (Wien). 2006 Jun;148(6):685-9; discussion 689. doi: 10.1007/s00701-006-0731-7. Epub 2006 Mar 2.

Abstract

Moyamoya ("hazy puff-of-smoke") disease represents a rare condition with progressive narrowing and occlusion of basal cranial vessels with secondary specific neoangiogenesis; we report on a 25-year-old primigravida with known moyamoya disease who suffered from acute bilateral intraventricular haemorrhage at 24 weeks gestation. She underwent bilateral external ventricular drainage and intraventricular recombinant tissue plasminogen activator (r-TPA) lysis was performed. At 34 weeks' gestation, a healthy girl was delivered via Caesarean section. Encephalomyosynangiosis (EMS) and extra-intracranial (EC/IC) bypass surgery were performed six and eight months after delivery, respectively. The patient recovered almost completely and showed only mild residual deficits. Prompt diagnosis and immediate interdisciplinary treatment might have been the key for optimal maternal and neonatal outcome in our patient.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Cerebral Angiography
  • Cerebral Arteries / diagnostic imaging
  • Cerebral Arteries / pathology
  • Cerebral Arteries / physiopathology
  • Cerebral Hemorrhage / etiology*
  • Cerebral Hemorrhage / physiopathology*
  • Cerebral Hemorrhage / therapy
  • Cerebral Revascularization
  • Cerebral Ventricles / pathology
  • Cerebral Ventricles / physiopathology
  • Cerebral Ventricles / surgery
  • Female
  • Humans
  • Intracranial Hypertension / etiology
  • Intracranial Hypertension / physiopathology
  • Moyamoya Disease / complications*
  • Moyamoya Disease / physiopathology*
  • Pregnancy
  • Pregnancy Complications, Cardiovascular / etiology*
  • Pregnancy Complications, Cardiovascular / physiopathology*
  • Pregnancy Complications, Cardiovascular / therapy
  • Recovery of Function
  • Tissue Plasminogen Activator / therapeutic use
  • Treatment Outcome
  • Ventriculostomy

Substances

  • Tissue Plasminogen Activator